Ideas to action: independent research for global prosperity
Search
Filters:
Experts
Facet Toggle
Topics
Facet Toggle
Content Type
Facet Toggle
Publication Type
Facet Toggle
Article Type
Facet Toggle
Time Frame
Facet Toggle
CGD NOTES
March 20, 2023
With global challenges high on the international agenda and financing set to increase in the coming years, a big push on evidence, backed by dedicated resources, is essential. This note makes the case for a reinvigorated evidence agenda to boost the impact of financing for development and global pub...
Blog Post
March 07, 2023
The EU and its member states are collectively the world’s largest aid donor, with an annual budget of over $70 billion in 2021. When it comes to global health, however, it has historically punched below its weight. In part, this is due to an internal coordination problem; health is a shared competen...
Mar
7
2023
VIRTUAL
9:30—10:45 AM Eastern Time (US and Canada)
February 27, 2023
Following promising clinical trial results, the first oral antiviral treatments for COVID-19 received emergency use authorization in late 2021. Since then, manufacturers, global health funders, and other partners have focused on ramping up global supply, including via test-and-treat pilot programs. ...
Blog Post
January 25, 2023
Last month, the Center for Global Development (CGD), the White House Office of Science and Technology Policy, and the Office of Management and Budget co-hosted an Evidence Forum as part of the White House Year of Evidence for Action, featuring USAID Administer Samantha Power. The event celebrated pr...
CGD NOTES
January 17, 2023
This CGD note summarizes the implications of the macroeconomic context and broader financing outlook for domestic and external health spending and proposes a “menu” of policy options to keep health spending on track and blunt negative impacts on health systems and population health around the world.
CGD NOTES
December 14, 2022
Almost a year after two oral antiviral treatments received emergency use authorization, demand is extremely low. In this note, we argue that governments and their donor partners should use data and evidence to consider the economic and clinical rationale for registering, financing, purchasing, and d...
Blog Post
December 14, 2022
Four new CGD pieces, released today, examine the current state of play on COVID-19 oral antivirals. Our analyses provide a deep-dive in key cross-cutting areas—demand, voluntary licensing deals for generic supply, and deployment—and offer policy actions for 2023 and beyond.
Press Release
November 16, 2022
The Latin American Committee on Macroeconomic and Financial Issues (CLAAF, by its Spanish acronym) today praised the central banks of Brazil, Mexico, Chile and Peru for taking swift and aggressive action to address growing inflation – and urged them to stay the course, as conquering inflation will b...
Blog Post
August 10, 2022
PEPFAR’s new strategy—to be released in final form later this year—focuses on how to accelerate progress toward epidemic control amidst continued impacts from COVID-19, while also strengthening core health system functions as well as partnership and coordination efforts; this is precisely what the c...
BRIEFS
July 19, 2022
This brief summarizes the final report of the working group. The report collates resources and insights on progress in implementing and using impact evaluations for decision making and proposes five ways to improve impact evaluation funding and practice, directed to the development community